Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by themagicboxon Jul 14, 2020 9:53am

179 Views

Post# 31264754

RE:RE:Uplisting to NASDAQ

Im actually with Dan on this one. They shouldnt just uplist asap.

The best time to uplist would've been a month ago prior to results. Dan messed this one up, hard!

I think uplisting to appease the whiners, could be more harmful. So i think they'll wait for a catalyst prior to uplisting to ensure they trade well once they're up.

MUGMODs wrote: They would become listed on the second exchange as well. I think it’s called cross-listing. It seems very simple ... as an example, see PRN on the TSX and it is cross-listed on the NASDAQ as PROF.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide